Preclinical study demonstrates combination of PARP and AKT inhibitors intercepts tumors in a mouse model, suggesting targeted therapy benefits.
We utilized the K14-Cre Brca1 f/f Tp53 f/f mouse model to investigate whether a pulse of PARP inhibitor (PARPi) ± an AKT inhibitor (AKTi) can prevent Brca1 -related breast cancer. PARPi alone did not intercept or prevent tumor development. PARPi+AKTi intercepted tumors but did not prevent new tumors. These data confirm the efficacy of a PARPi and an inhibitor of PI3K signaling in treating BRCA1/2 -related tumors, but this combination is not sufficient to prevent carcinogenesis.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: